Literature DB >> 12499229

In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.

Patrick Grohs1, Marie-Dominique Kitzis, Laurent Gutmann.   

Abstract

The in vitro activities of linezolid were determined alone and in combination with vancomycin, ciprofloxacin, gentamicin, fusidic acid, or rifampin against five methicillin-susceptible Staphylococcus aureus (MSSA) and five methicillin-resistant S. aureus (MRSA) strains. Similar responses were obtained against MSSA and MRSA. When combined with fusidic acid, gentamicin, or rifampin, linezolid prevented selection of resistant mutants but showed no synergy. When linezolid was combined with vancomycin and ciprofloxacin, a slight antagonism was observed. While the combination with linezolid may reduce the emergence of mutants resistant to the associated drugs, the absence of synergy, especially in the case of vancomycin and ciprofloxacin, does not argue in favor of such combinations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499229      PMCID: PMC148978          DOI: 10.1128/AAC.47.1.418-420.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

Authors:  C W Ford; J C Hamel; D M Wilson; J K Moerman; D Stapert; R J Yancey; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Authors:  D C Eustice; P A Feldman; I Zajac; A M Slee
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

4.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  In vitro activity of fosfomycin in combination with various antistaphylococcal substances.

Authors:  K Grif; M P Dierich; K Pfaller; P A Miglioli; F Allerberger
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

6.  Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.

Authors:  M J Rybak; D M Cappelletty; T Moldovan; J R Aeschlimann; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.

Authors:  R Patel; K E Piper; M S Rouse; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

View more
  27 in total

1.  Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.

Authors:  Wolfgang A Krueger; Bernd Kottler; Bernd E Will; Alexandra Heininger; Heinz Guggenberger; Klaus E Unertl
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Effective CSF concentrations achieved with continuous-infusion flucloxacillin in a child.

Authors:  Alison Boast; Jeremy Carr; Nigel Curtis; Andrew J Daley; Amanda Gwee
Journal:  Eur J Clin Pharmacol       Date:  2015-08-26       Impact factor: 2.953

3.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Brian J Werth
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

5.  Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

6.  Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.

Authors:  Megan K Luther; Marios Arvanitis; Eleftherios Mylonakis; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.

Authors:  Raluca Mihailescu; Ulrika Furustrand Tafin; Stéphane Corvec; Alessandra Oliva; Bertrand Betrisey; Oliver Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Comparison of In-vitro Activities of Linezolid and Vancomycin against Staphylococcus aureus Isolated from A Tertiary Care Hospital.

Authors:  Sachin Kishore; Deepika Verma; Me Siddique
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 10.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.